ARCA Biopharma Inc (ABIO)

Stock Card

$2.48

$-27.52 (-91.73%)

As on 30-Aug-2024 19:22EDT

Market cap

$35 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

P/B Ratio

1.1

Div. Yield

0 %

ARCA Biopharma Inc (ABIO) Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: -- High: --

52 Week Range

Low: -- High: --

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$-1 Mln
ROE

-0.2 %
ROCE

-- %
Industry P/E

--
EV/EBITDA

-1.4
Debt to Equity

0
Book Value

$--
EPS

$--
Face value

--
Shares outstanding

1,208,930

10 Years Aggregate

CFO

$-107.86 Mln

EBITDA

$-116.09 Mln

Net Profit

$-113.06 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
ARCA Biopharma Inc (ABIO)	-87.8	-93.3	-94.0	-90.0	-59.2	-48.5	-49.1
BSE Sensex^*	-8.8	0.6	1.8	-4.4	6.0	6.6	10.8
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 30-Aug-2024 | *As on 28-Aug-2026 | #As on 26-Oct-2023

Company	2023	2022	2021	2020	2019	2018	2017
ARCA Biopharma Inc (ABIO)	-28.3	10.2	-46.4	-29.8	-4.9	-75.1	-52.6
S&P Small-Cap 600	13.9	-17.4	25.3	9.6	20.9	-9.7	11.7
BSE Sensex	18.7	4.4	22.0	15.8	14.4	5.9	27.9

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Peers

View Details

Company	Price ($)	Market Cap ($ Mln)	Revenue (TTM)	Net Profit (TTM)	OPM (%)	ROE (%)	P/E	P/B
ARCA Biopharma Inc (ABIO)	2.5	34.8	0.2	-7.2	-4,994.9	-20.7	--	1.1
Agile Therapeutics (AGRX)	1.5	10.4	21.6	-15.9	-33.5	--	--	1.8

Shareholding Pattern

View Details

About ARCA Biopharma Inc (ABIO)

ARCA biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacogenetically-targeted... beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with heart failure. It is developing Recombinant Nematode Anticoagulant Protein c2, a protein therapeutic that is in Phase IIb clinical trial for the treatment for COVID-19. The company has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial. ARCA biopharma, Inc. is headquartered in Westminster, Colorado. Read more

Co-Founder, President, CEO & Director

Dr. Michael R. Bristow M.D., Ph.D.
Co-Founder, President, CEO & Director

Dr. Michael R. Bristow M.D., Ph.D.
Headquarters

Westminster, CO
Website

https://www.arcabio.com

FAQs for ARCA Biopharma Inc (ABIO)

What is the current share price of ARCA Biopharma Inc (ABIO) Today?

The share price of ARCA Biopharma Inc (ABIO) is $2.48 (NASDAQ) as of 30-Aug-2024 19:22 EDT. ARCA Biopharma Inc (ABIO) has given a return of -59.23% in the last 3 years.

What is the current PB & PE ratio of ARCA Biopharma Inc (ABIO)?

Since, TTM earnings of ARCA Biopharma Inc (ABIO) is negative, P/E ratio is not available.
The P/B ratio of ARCA Biopharma Inc (ABIO) is 1.07 times as on 06-Sep-2024, a 80 discount to its peers’ median range of 5.35 times.

PE & PB ratio at the end of financial year.

Year	P/E Ratio	P/B Ratio
2023	--	--
2022	--	--
2021	--	--
2020	--	--
2019	--	--

What is the 52 Week High and Low of ARCA Biopharma Inc (ABIO)?

The 52-week high and low of ARCA Biopharma Inc (ABIO) are Rs -- and Rs -- as of 30-Aug-2026.

What is the market cap of ARCA Biopharma Inc (ABIO)?

ARCA Biopharma Inc (ABIO) has a market capitalisation of $ 35 Mln as on 06-Sep-2024. As per SEBI classification, it is a Small Cap company.

Should I invest in ARCA Biopharma Inc (ABIO)?

Before investing in ARCA Biopharma Inc (ABIO), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.

For guidance, explore our expert-curated portfolios and Stock recommendations with Value Research Stock Advisor.

Want to explore on your own? Click here to see how this stock scores on quality, growth, valuation, and momentum.